Shares of Cardlytics (CDLX) are moving higher after Andrew Left’s Citron Research, best known for its short selling reports, listed the top reasons to buy the stock. ” Citron pounds the table and now is the time to look at $CDLX as the wind is finally at their back,” the firm said in a report on its website. Cardlytics shares are up 22%, or 46c, to $2.55 in afternoon trading. The firm sees $10 per share as a “reasonable” price target “that can happen with just one” customer announcement. Signing up a major publisher on Cardlytics’ rewards platform “changes this company overnight, and helps the consumer,” Citron contends.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDLX:
- Cardlytics benefits from Wells Fargo push into cards, Citron says
- Largest borrow rate increases among liquid names
- Cardlytics, Inc. Balances Growth and Challenges in Earnings Call
- Cardlytics: Balancing Growth with Uncertainty – Hold Rating Amidst Partnership and Stability Concerns
- Cardlytics Reports Q2 2025 Financial Results